-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Taysha Gene Therapies, Maintains $8 Price Target

Benzinga·07/01/2025 10:27:41
Listen to the news
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $8 price target.